Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary Acceleron Announces Publication of ACE-083 Phase 1 Trial Results in Muscle & Nerve
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2018-- Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the journal Muscle & Nerve has published the final results
View HTML
Toggle Summary Acceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial Results
– Top-line results from the MEDALIST and BELIEVE Phase 3 trials of luspatercept are expected in mid-2018 – – Plans to advance neuromuscular agent ACE-083 into Part 2 of the ongoing Phase 2 trials in facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease – – Expanded pipeline with sotatercept
View HTML
Toggle Summary Acceleron to Webcast Fourth Quarter and Full Year 2017 Operating and Financial Results on February 27, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 20, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, February 27, 2018 at 5:00 p.m. EST to discuss its fourth quarter and full year 2017 operating and financial results.
View HTML
Toggle Summary Acceleron Announces Appointment of Chief Commercial Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 8, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the appointment of commercial industry leader, Sujay Kango as
View HTML
Toggle Summary Acceleron to Present at the Leerink Partners 7th Annual Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 31, 2018-- Acceleron Pharma Inc.  (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that members of the management team will present at the Leerink
View HTML
Toggle Summary Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--  Acceleron Pharma Inc.  (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced positive preliminary results for the first two cohorts in Part 1 of the Phase 2
View HTML
Toggle Summary Acceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. Sherman
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the planned retirement of Executive Vice President and Chief
View HTML
Toggle Summary Acceleron to Webcast Presentation at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 2, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that Habib Dable, President and Chief Executive Officer, will
View HTML
Toggle Summary Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology
- Preliminary results show treatment with luspatercept increases hemoglobin and achieves durable red blood cell transfusion independence in patients with lower-risk myelodysplastic syndromes - - Conference call and webcast to be held on Monday, December 11 th at 7:00 a.m. EST - CAMBRIDGE, Mass.
View HTML
Toggle Summary Acceleron to Host Conference Call and Webcast to Review Data Presented at the 59th American Society of Hematology Annual Meeting and Exposition
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) will host a conference call and live audio webcast on Monday, December 11, 2017 at 7:00 a.m. EST to review highlights from its Phase 2 clinical presentations at the 59th American Society of Hematology (ASH) Annual Meeting and
View HTML